A phase II trial of docetaxel in the treatment of elderly patients (aged 70 or over) with non-small cell lung cancer

Completed

• Conditions: Advanced stage non small cell lung cancer; Cancer; Non small cell lung cancer

• Registration Number: ISRCTN27242710
• Lead Sponsor: Maidstone and Tunbridge Wells NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-14
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

1. Aged greater than or equal to 70 on the day of first treatment
2. Histologically or cytologically confirmed NSCLC
3. Any stage not suitable for surgery or radical radiotherapy
4. Radiologically evaluable disease (by Response Evaluation Criteria In Solid Tumours [RECIST] criteria) of at least one measurable lesion on chest X-ray (CXR) or computed tomography (CT)
5. Performance status World Health Organization (WHO) of 0, 1 or 2
6. Life expectancy greater than 12 weeks
7. Adequate haematological and biochemical function

Exclusion Criteria

1. Prior chemotherapy (previous surgery and palliative radiotherapy are allowed)
2. Uncontrolled non-cancer systemic disease
3. Significant clinical or laboratory abnormalities
4. Concomitant or previous malignancy likely to interfere with treatment outcome
5. WHO performance status of worse than 2
6. Inadequate renal function
7. Inadequate bone marrow function

Study & Design

• Study Type: Interventional
• Study Design: Not specified